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Background: The role of DM as a risk factor for cognitive decline in later life has received little epidemiological 
attention until recently. This is despite the high prevalence of diabetes (especially type 2) in older populations. 
Objective: To compare between the risk of development of Alzheimer disease (AD) in patients with and without non-
insulin dependent diabetes mellitus (NIDDM). Methods: This study is a longitudinal cohort study. For up to 2 years, 764 
subjects underwent annual evaluation that included medical history, neurological examination, neuropsychological 
performance testing, and review of a brain scan when available. For a diagnosis of probable Alzheimer's disease, the 
criteria adapted from the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer’s 
disease and Related Disorders Association (NINCDS-ADRDA). Results: Diabetes mellitus was present in 106 (13.9%) 
of the participants. During a mean of 2 years of observation, 137 persons developed AD. In a proportional hazards model 
adjusted for age, sex, and educational level, those with diabetes mellitus had a 61% increase in the risk of developing AD 
compared with those without diabetes mellitus (hazard ratio, 1.53; 95% confidence interval, 0.96-2.45). The risk of 
incident dementia was clearly modified by baseline treatment), with the lowest relative risk in newly discovered or 
untreated diabetic patients (RR 1.3, 95% CI 0.7 to 2.3) and the highest RR among patients treated with insulin (RR 4.3, 
95% CI 1.7 to 10.5). Conclusion: Patients with NIDDM; particularly those treated with insulin may be at an increased 
risk of developing AD. [Egypt J Neurol Psychiat Neurosurg. 2010; 47(3): 419-424] 
 





The role of DM as a risk factor for cognitive 
decline in later life has received little 
epidemiological attention until recently. This is 
despite the high prevalence of diabetes (especially 
type 2) in older populations, the high prevalence of 
dementia, and several potential mechanisms; by 







, diabetes mellitus 
has been associated with various
 
adverse health 
effects, including cognitive impairment. The
 
association of diabetes mellitus with impaired 
cognitive function
 
suggests that diabetes mellitus 
may contribute to Alzheimer
 
disease (AD). 
However, few prospective studies have 
examined
 
the association between diabetes mellitus 
and incident AD, and
 
their results have been 
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Many factors may mediate an association 
between diabetes and AD. A post-mortem study of 
brains of diabetic patients found no evidence of 
increased Alzheimer's pathology compared to age-
matched controls 
[9]




The aim of this study was to compare the risk 
of developing AD in subjects
 
with and without DM. 
 
SUBJECTS AND METHODS 
 
A number of 876 patients referred to the 
Department of Neuropsychiatry, El-Menoufia 
University and Tanta University Hospitals were 
enrolled in this study starting from January 2006 to 
January 2008. The mean age was 68±4 years. Sixty-
tow (7.0%) had dementia at baseline and
 
were 
excluded from all analyses.  
Of the 814 participants without
 
dementia, 19 
died before the first follow-up evaluation and 31 
enrolled in the previous year and had not yet reached 
the
 
scheduled date of their first follow-up evaluation.  
This left 764 persons eligible for follow-up. 
Analyses were based on this group of patients,
 
who 
underwent annual clinical evaluations.  
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Missing data have reflected relocation, 
withdrawal
 
from all or part of the study, and 
incapacity or unwillingness
 




All patients gave their informed consent and 




1- Patients having mixed vascular and Alzheimer 
dementia. Vascular dementia was diagnosed by 
sudden or stroke-related onset, presence of 
lateralizing neurological signs, and MRI brain. 
2- Patients having other types of dementia. 
3- Patients having dementia at the baseline of the 
study. 
4- Patients who develop diabetes mellitus after 
the onset of AD during the period of follow up. 
5- Patients having type-I DM. 
6- Presence of pseudo-dementia (depressive 
disorder). 
 
At baseline, each subject underwent a uniform 
structured
 
clinical evaluation that followed the 
procedures recommended
 
by the Consortium to 
Establish a Registry for Alzheimer's disease. The 
evaluation included medical history, neurological 
examination, neuropsychological performance 
testing in the form of MMSE test, and review of a 
brain
 
scan when available. The CT brain was 
restricted to those having straight forward 
radiological diagnosis and did not need more 
verification by MRI brain.  
 
For a diagnosis of probable Alzheimer's, the 
criteria adapted from the National Institute of 
Neurological and Communicative Disorders and 
Stroke and Alzheimer’s disease and Related Disorders 
Association (NINCDS-ADRDA) include:  
 Dementia established by examination and 
objective testing  
 Deficits in two or more cognitive areas  
 Progressive worsening of memory and other 
cognitive functions  
 No disturbance in consciousness  
 Onset between ages 40 and 90. 
         
Diabetes mellitus was considered present if the 
participant
 
was taking a medication to treat diabetes 
mellitus, reported
 
a history of diagnosis of diabetes 
mellitus, or both.  
Follow-up evaluations were identical in all 
essential
 
details to the baseline evaluation, and were 
performed annually
 
by examiners blinded to 
previously collected data.                          
 
Statistical Methods 
All analyses adjusted for age, sex, and 
educational level. Cox
 
proportional hazards models 
were used to estimate the risk of
 
AD among persons 





Random effects models were used to test the 
effects of diabetes
 
mellitus on baseline level of 
function and annual rate of change
 
(fixed effects) 
while adjusting for person-specific paths of
 
cognitive 






mellitus was present in 106 (13.9%) 
out of the 764 participants included in these analyses 
at baseline. Out of the
 
106 participants with diabetes 
mellitus, 96 (90.57%) were taking medication
 
for the 
treatment of diabetes mellitus: 46 were taking
 
insulin 
only, 40 were taking an oral
 
hypoglycemic only, 10 
were taking both and 10 patients were under no 
treatment at all.
 
Overall, there were more men in the 
group with diabetes mellitus
 
(Mentioned table). 
During the follow-up evaluations, 137 persons 
developed AD,
 
of whom 25 had diabetes mellitus. 
(In a proportional hazards
 
model adjusted for age, 
sex, and educational level), there was
 
a 61% increase 
in the risk of developing AD in those with diabetes
 
mellitus compared with those without diabetes 
mellitus (hazard ratio, 1.53; 95% confidence 
interval, 0.96-2.45) The cumulative
 
hazard of AD 
over time, adjusted for age, sex, and educational
 
level, is shown graphically in Figure 1 for typical 
participants
 
with and without diabetes mellitus.  
The risk of incident dementia was clearly 
modified by baseline
 
treatment, with the lowest 
relative risk in newly
 
discovered or untreated 
diabetic patients (PR 1.3, 95 % CI 0.7 to 2.3) and the 
highest RR among patients treated with insulin (RR 
4.3, 95% CI 1.7 to 10.5). 
 
Table 1. General Characters of the sample. 
  
Characteristic 
Subjects with diabetes mellitus  
N = 106 
Subjects without diabetes mellitus  
N = 658 
Age at base line 
Male sex, No. (%) 
Education, Y 




26.2 ( 1.5 




Data are expressed as mean (SD) unless otherwise indicated 
MMSE Mini-Mental State Examination.   
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Table 2. MMSE Scores of the Alzheimer’s disease patients with and without Diabetes mellitus. 
 
MMSE Scores 
Subjects with DM 
No=106 
Subjects without DM 
No=658 
≤ 10 1 2 
11-15 19 43 
16-19 22 57 
20-22 15 10 
23-24 14 93 
25 12 154 
27-28 16 177 
29-30 7 142 
Total 106 658 
DM Diabetes mellitus, MMSE Mini-Mental State Examination.  
 
Table 3. Types of treatment of diabetes mellitus in diabetic Alzheimer’s disease patients. 
  
Type of Treatment  Number Percentage (%) 
Under insulin 46 43.41 
Under oral treatment  40 37.73 
Under both  10 9.43 
Not under treatment  10 9.43 
Total 106 100 
 
Table 4. MMSE Orientation scores of Alzheimer’s disease patients with and without Diabetes mellitus.   
 
Scores of Orientation 
Diabetic  Non Diabetic  
Number Percentage (%) Number Percentage (%) 
0 – 3 13 52 47 41.96 
4 – 6 8 32 38 33.93 
7 – 10 4 16 27 24.11 
Total 25 100 112 100 
No statistically significant difference was found between diabetic and non diabetic patients as regard orientation (p>0.05). 
MMSE Mini-Mental State Examination. 
 
Table 5. MMSE scores of attention & calculation of Alzheimer’s disease patients with and without Diabetes 
mellitus.  
   
Scores of Attention & 
Calculation  
Diabetic  Non Diabetic  
No % No % 
0 – 2 16 64 53 47.32 
3 – 4 7 28 42 37.50 
5 2 8 17 15.18 
Total 25 100 112 100 
A statistically significant difference was found between diabetic and non-diabetic patients as regard attention and calculation (p<0.05). 
MMSE Mini-Mental State Examination. 
 
Table 6. MMSE scores of recall of the Alzheimer’s disease patients with and without Diabetes mellitus. 
    
Scores of Recall   
Diabetic  Non Diabetic  
No % No % 
0 17 68 25 22.32 
1 4 16 45 40.18 
2 2 8 30 26.78 
3 2 8 12 10.72 
Total 25 100 112 100 
A statistically significant difference was found between diabetic and non diabetic patients as regard recall (p<0.001). 
MMSE Mini-Mental State Examination. 
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DISCUSSION 
 
In this study on more than 800 older persons, 
we found that diabetes
 
mellitus was associated with 
an increased
 
risk of developing AD during 2 years of 
observation.
 
The risk of incident AD was 61% 
higher in those with diabetes
 
mellitus than in those 
without it. These results
 
suggest that diabetes 





These findings are consistent with the results 







found that diabetes mellitus doubled
 
the risk of AD 
during 2 years of follow-up in a sample of more
 
than 





using data from about 2500 Japanese American 
men, found a similar
 
result: diabetes mellitus 
approximately doubled the risk of
 
AD. Xu et al., 
found that the risk of incident AD was 65% higher 
in those with diabetes
 
mellitus than in those without 
it. It is found recently that even borderline diabetes 
is associated with increased risks of dementia and 
Alzheimer's disease; the risk effect is independent of 
the future development of diabetes
10
.  





a significant association between 
diabetes mellitus and incident
 
AD, but in both, the 





in the Framingham cohort, overall Diabetes mellitus 
did not increase the risk of incident AD; however, 
DM may be a risk factor for AD in the absence of 
other known major AD risk factors
11
.  
Some case-control studies have reported a 
negative association between type 2 DM and AD
12-14
 
that suggested a possible protective effect of high 
glucose on the brain, but these studies have been of 
small size or have used referred patients with AD 
open to selection bias
15
.          
The basis of the association between diabetes 
mellitus and AD
 
is uncertain. The burden of 
Alzheimer's pathology may be increased by systemic 
vascular disease. The distribution of amyloid in 
white matter was found to be related to blood 
vessels, suggesting a vascular rather than a neuronal 
source
16
. Increased permeability of the blood-brain 
barrier occurs secondary to transient ischaemia
17
, 
and this process may underlie both perivascular 
amyloid deposition and white matter lesions
18
.  
However, the increased risk of AD associated 
with type 2 DM may be mediated to a large extent 
by non-vascular mechanisms
19
. These may include 
hyperglycemia compounding the ischemic burden of 
pre-existing vascular disease by increasing anaerobic 
metabolism and lactic acidosis
20
. 
In addition, the disturbances of 
neurotransmitters may be involved as decreased 
cholinergic transport across the blood-brain barrier 
which may be potentially important in exacerbating 
cognitive impairment in the presence of subclinical 
AD
21
. Butyrylcholinesterase and acetylcholine-
esterase related proteins were found common to both 
Alzheimer's disease and diabetes; they may play an 
etiological role via influencing insulin resistance and 
lipid metabolism
22
. Also, diabetes may have a role in 
dysfunctional glutamate receptors leading to an 
impaired hippocampal synaptic plasticity
23
.  
Our results showed that the lowest relative risk 
of developing AD was in newly
 
discovered or 
untreated diabetic patients and the highest RR 
among patients treated with insulin. This is in 
agreeing with the study that showed particular strong 
associations between dementia and diabetes treated 
with insulin. The relation was strongest with 
vascular dementia, but was also observed with AD
24
. 
Many important components of Alzheimer's 
disease appear to stem from imbalances in insulin 
signaling intrinsic to the brain, rather than systemic 
insulin imbalances, and that treatments aimed at 




Insulin has been shown to inhibit synaptic 
activity at excessively high or low levels
26
, and 
down regulate choline acetyltransferase
27
. Moreover, 
a role for insulin and insulin growth factor-1 (IGF-1) 
in the regulation of tau protein phosphorylation has 
been suggested
28
, the process underlying the 
formation of neurofibrillary tangles. IGF-1 prevents 
amyloid-related neurotoxicity in rats
29
. Deposition of 
amyloid deposit in pancreatic islet beta cells appears 
to be a consistent pathologic marker in type 2 DM. 
An islet peptide known as amylin has been identified 
as the key component of such amyloid deposit
32
. 
Janson et al. have recently reported an increased 
frequency of islet amyloid deposition in the pancreas 
of patients with AD compared with control subjects 
without AD
31
. Amylin antagonized insulin-induced 
glycogen synthesis in diabetes
32
. Polymorphic 
variations in genes involved in mediation of insulin 
metabolic effects and correlated with increased 
insulin resistance appear to contribute to the risk of 
AD, supporting the hypothesis that both diseases 
may share a common genetic background
33
. Chronic 
hyperglycemia and advanced age may be associated 




This study has some strengths including the 
availability of a period of 5 years of follow-up data 
with annual structured evaluations. Also, this 
longitudinal study benefits from a high
 
follow-up 
rate, which minimizes selective attrition effects.
 
Also, the homogeneity of the population may be
 
considered strength of the study, by controlling for 
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the effects
 






This study also has several limitations. The 
identification of persons
 
with diabetes mellitus. 
Diabetes mellitus was identified using
 
medication 
data and/or self-report, but not serological data.
 
However, analyses of data on inspection of all 
medications and
 
on self-report suggested that self-
report was a reliable means
 




In summary, these findings suggest that 
diabetes mellitus is
 
associated with increased risk to 
AD.  
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 دراسة مخاطر حذوث مرض الزهاٌمر إكلٍنٍكٍاً فً مرضً البول السكري
 
 .المقارنة بين مخاطر حدوث الزهايمر في مرضي البول السكري :الهدف من البحث 
اريخ شخص وأجريت لهم تقييم شمل الت 427عمى  6002إلي  6002أجريت هذه الدراسة خالل سنتين فى الفترة من : طريقة البحث 
شعة مقطعية عمى المخ لبعض مع عمل أ MMSEالمرضي، اختبار الجهاز العصبي واالختبارات النفسية العصبية في صورة مقياس 
 . المرضي
مريض من المشاركين في البحث وفى خالل عامين من المالحظة والمتابعة  602كان مرض البول السكري يوجد عند : النتائج 
مريض لم يعانوا من  666ممن أصيبوا بمرض البول السكري و 62ا إكمينيكيًا أعراض مرض الزهايمر منهم أظهرو  634لممرضي وجد أن 
  .مرض البول السكري
فددي خطددورة تعرضددهم لمددرض %  26وقددد وجددد مددن النتدداالء أن هدد الل انشددخاص الددذين يعددانون مددن مددرض البددول السددكري يزيدددون بنسددبة 
يعددانون مددن مددرض البددول السددكري وكددذلة وجددد أن نسددبة مددرض الزهددايمر تقددل فددي هدد الل المرضددي بددالبول الزهددايمر بالمقارنددة مددع هدد الل الددذين ال 
العددالج بعددد وتددزداد النسددبة أكالددر فددي هدد الل المرضددي بددالبول السددكري كممددا زادت مدددة المددرض  السددكري فددي مرحمددة بدايددة المددرض والددذين لددم يبدددأو
 .والعالج باننسولين
وخاصة الذين يعالجون باننسولين يكونوا عرضة  أكالر ( NIDDM)عانون من مرض البول السكري أن المرضي الذين ي :الخالصة 
 .من غيرهم باإلصابة بمرض الزهايمر
